Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mifamurtide
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mifamurtide is a synthetic immunomodulator and a derivative of muramyl dipeptide (MDP), formulated as a liposomal preparation. It acts by activating monocytes and macrophages, primarily through interaction with the nucleotide-binding oligomerization domain 2 (NOD2) receptor, leading to nuclear factor kappa B (NF-kB) activation. This results in the production of proinflammatory cytokines and enhances both bactericidal and tumoricidal immune responses. Mifamurtide is used as an adjuvant therapy in combination with postoperative multi-agent chemotherapy for high-grade, resectable, non-metastatic osteosarcoma after complete surgical resection in children, adolescents, and young adults. The drug has demonstrated improved overall survival when added to standard chemotherapy regimens[1][2][3][4][5][8].
- Brand names
- MepactJunovan
- Other names
- mifamurtide sodium hydratesodium mifamurtidemuramyl tripeptide PEmuramylNAc-Ala-isoGln-Lys-tripeptide-PE
02
Targets
TLR4 (Toll-like receptor 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on mifamurtide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mifamurtide.